Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of Voxelotor in Healthy Men
NCT02497924Phase 1Completed
- Sponsor
- Global Blood Therapeutics
- Start
- Jun 2015
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of voxelotor in sickle cell disease (SCD), sponsored by Global Blood Therapeutics. Primary endpoints: Area under the whole blood and plasma concentration versus time curve, Peak whole blood and plasma concentration and 4 more. Started Jun 2015; status: completed.
02
Drugs
voxelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02497924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02497924.